Oncopeptides has broaden its management team with the appointment of Dr Christian Jacques as Executive Vice President Clinical Strategy and Chief Scientific Officer (CSO).
Jacques has more than 25 years of experience in clinical development of new chemical entity’s within hematology-oncology leading to approval of several innovative pharmaceuticals in oncology and hematology, including pomalidomide.
“The appointment of Dr Christian Jacques as EVP Clinical Strategy and Chief Scientific Officer is an important step in building the Oncopeptides organization. Dr Jacques will be leading the regulatory submission team for Ygalo globally as well as mapping out the clinical development strategy for both Ygalo and our pipeline candidates. Dr Jacques is one of the most experienced senior developers in multiple myeloma and hematology globally. It is a privilege to welcome him to the Oncopeptides management team. ” said Jakob Lindberg, CEO of Oncopeptides.
Christians Jacques is a MD in Internal Medicine with specialization in Hematology-Oncology. His previous positions include global Myeloma Therapeutic Area Head at Celgene Inc, Executive Director at Novartis Oncology, Global Senior Director Oncology at Johnson and Johnson and various positions at Aventis, Rhone-Poulenc and Pierre Fabre all in the field of oncology. Dr Jacques is also a member of the American Society of Hematology and a member of the American Society of Clinical Oncology.
